A open label phase II trial of cetuximab plus cisplatin in patients with recurrent or metastatic undifferentiated carcinoma of nasopharyngeal type: Results after three years.

Kerboua, Esma; Tahrat, Amina; Bouzid, K.

doi:10.1200/jco.2015.33.15_suppl.e17021

Cited by 1 publication

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nine phase II trials were identified. 9–11,15,18,20,24–26 Of 20 selected studies, 5 were presented in the form of abstracts only. The findings of the selected studies that describe the use of cetuximab in nasopharyngeal carcinoma (NPC) are summarised in Tables 1–8.…”

Section: Resultsmentioning

confidence: 99%

“…In two phase II trials, the toxicity and efficacy of cetuximab in combination with carboplatin 25 or cisplatin 26 in recurrent and/or metastatic NPC patients, in whom disease had progressed at or within 12 months following completion of platinum-based chemotherapy, were evaluated. The overall response rates (complete or partial response, and stable disease) were 60 per cent with carboplatin and 78 per cent with cisplatin.…”

Section: Resultsmentioning

confidence: 99%

“…The authors of both studies concluded that the regimens were clinically effective, with acceptable safety profiles. 25,26…”

Section: Resultsmentioning

confidence: 99%

“…The use of cetuximab in combination with chemotherapy was tested in two phase II trials (the total number of patients in these 2 trials was only 114). 25,26 The authors of both studies concluded that the regimens were clinically effective, with acceptable safety profiles. However, there has been criticism of these findings.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Cetuximab in the management of nasopharyngeal carcinoma – a narrative review

et al. 2019

View full text Add to dashboard Cite

BackgroundConcurrent chemotherapy with radiotherapy is the standard treatment for locoregionally advanced nasopharyngeal cancer. Cetuximab can be used in the treatment of head and neck squamous cell carcinoma. However, the randomised studies that led to approval for its use in this setting excluded nasopharyngeal cancer. In the context of limited data for the use of cetuximab in nasopharyngeal cancer in the medical literature, this review aimed to summarise the current evidence for its use in both primary and recurrent or metastatic disease.MethodA literature search was performed using the keywords ‘nasopharyngeal neoplasm’, ‘cetuximab’ and ‘Erbitux’.ResultsTwenty studies were included. There were no randomised phase III trials, but there were nine phase II trials. The use of cetuximab in the treatment of nasopharyngeal carcinoma has been tested in various settings, including in combination with induction chemotherapy and concurrent chemoradiotherapy, and in the palliative setting.ConclusionThere is no evidence of benefit from the addition of cetuximab to standard management protocols, and there is some evidence of increased toxicity. There is more promise for its use in metastatic or locally recurrent settings. This review draws together the existing evidence and could provide a focus for future studies.

show abstract